Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma ...Middle East

RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation study (NCT03145181) of teclistamab (JNJ-64007957) for the treatment of relapsed or refractory...

Hence then, the article about updated results from the phase 1 study of the bcmaxcd3 bispecific teclistamab show preliminary efficacy in patients with heavily pretreated relapsed or refractory multiple myeloma was published today ( Saturday 05/12/2020 - 11:46 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma )

Also on site :

• Celine Dion to Make Concert Comeback in Paris
• How Chuck Norris Created the Manosphere
• Hacks' Deborah Vance Fights To Reclaim The Spotlight In Final Season Trailer — Plus, Get Premiere Date